Patient-Reported Outcomes For Organ Transplant Drugs Could Learn From Other Fields
US FDA staff suggest that oncology and rheumatology instruments could be leveraged or supplemented to make them fit for purpose in assessing toxicity of immunosuppressive regimens in transplant recipients.
